Neo Comprehensive - Myeloid Disorders

The Neo Comprehensive- Myeloid Disorders assay analyzes 163 genes to detect DNA and RNA alterations through next-generation sequencing (NGS) as noted below. Test reports include a summary interpretation of all results together. DNA sequencing SNVs/Indels (126 genes): ABL1, ANKRD26, APC, ARAF, ASXL1, ATM, ATRX, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CHEK2, CSF3R, CTC1, CUX1, CXCR4, DDX41, DKC1, DNMT3A, ELANE, EPCAM, ERCC4, ETNK1, ETV6, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FLT3, G6PC3, GATA1, GATA2, GFI1, GNAS, GNB1, HAX1, HRAS, IDH1, IDH2, IKZF1, IKZF3, ITPKB, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MAP2K1, MET, MLH1, MPL, MSH2, MSH6, MYD88, NF1, NHP2, NOP10, NOTCH1, NPM1, NRAS, PALB2, PDGFRA, PHF6, PIGA, PML, PMS2, PPM1D, PTEN, PTPN11, RAD21, RAD51C, RB1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS26, RPS7, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SLX4, SMC1A, SMC3, SRP72, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TERC, TERT, TET2, TINF2, TP53, U2AF1, VHL, WAS, WRAP53, WT1, ZRSR2 Copy Number Variants (CNV) (17 genes): ABL1, ASXL1, ATG2B, BRAF, CBFB, CDKN1B, CDKN2A, DNMT1, ETV6, EZH2, GSKIP, JAK2, KMT2A, KRAS, MYC, RAD21, TP53 RNA sequencing Fusions (40 genes): ABL1, AFDN, AFF1, ALK, BCL11B, CBFB, CEP43, CPSF6, CREBBP, DEK, ELL, EP300, ETV6, FGFR1, FLT3, GLIS2, JAK2, KMT2A, MECOM, MLLT1, MLLT3, MRTFA, MYB, MYH11, NTRK3, NUP214, NUP98, PCM1, PDGFRA, PDGFRB, PICALM, PML, PRDM16, RARA, RBM15, RPN1, RUNX1, RUNX1T1, TCF3, ZNF384 Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the Neo Comprehensive Myeloid Disorders. It is reported separately from the Neo Comprehensive profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.